As of June 10, 2025, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) reports a ROA (Return on Assets) of 0.72%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROA (Return on Assets)
Over recent years, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 0.72% |
| 2023-12-31 | 7.94% |
| 2022-12-31 | 29.18% |
| 2021-12-31 | 28.69% |
| 2020-12-31 | 19.32% |
This slight upward trend highlights how Beijing Wantai Biological Pharmacy Enterprise Co Ltd manages its efficiency in using assets to generate earnings over time.
Comparing Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROA (Return on Assets) to Peers
To better understand Beijing Wantai Biological Pharmacy Enterprise Co Ltd's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) | 0.72% |
| Xiamen Amoytop Biotech Co Ltd (688278.SS) | 27.13% |
| Imeik Technology Development Co Ltd (300896.SZ) | 23.47% |
| Shenzhen New Industries Biomedical Engineering Co Ltd (300832.SZ) | 19.01% |
| Anhui Anke Biotechnology Group Co Ltd (300009.SZ) | 13.77% |
| Amoy Diagnostics Co Ltd (300685.SZ) | 12.34% |
Compared to its competitors, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROA (Return on Assets) is among the lowest compared to peers, suggesting potential inefficiency in asset utilization.